Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown - - All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101.
WALTHAM, Mass., Jan. 03, 2024 Dyne Therapeutics, Inc. , a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically.